- Molecular NamePerhexiline
- Synonym(-)-2-(2,2-Dicyclohexylethyl)piperidine; (+)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine; Perhexilene; Perhexilina [INN-Spanish]; Perhexilinum [INN-Latin]; Perhexilline
- Weight277.496
- Drugbank_IDDB01074
- ACS_NO6621-47-2
- Show 3D model
- LogP (experiment)6.054
- LogP (predicted, AB/LogP v2.0)5.62
- pkaN/A
- LogD (pH=7, predicted)2.56
- Solubility (experiment)0.0608 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.8
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors1
- No.of HBond Acceptors1
- No.of Rotatable Bonds4
- TPSA12.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyA prophylactic antianginal agent
- Absorption_value80.0
- Absorption (description)Well absorbed (>80%) from the gastrointestinal tract following oral administration.
- Caco_2N/A
- Bioavailability73.5
- Protein binding90.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmSaturable Hepatic
- Half life2~6 days; it could be as long as 30 days
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityShort term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
- LD50 (rat)LD50=2150 mg/kg
- LD50 (mouse)LD50=2641 mg/kg